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*Department of Internal Medicine, Marshall University School of Medicine, Huntington, WV, †Critical Care Medicine, National Institute of 
Health, Bethesda, MD, ‡Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, §Department of Internal Medicine, 
Healthcare Research Institute, Seoul National University Hospital Healthcare System, Seoul, Korea, and ∥Division of Gastroenterology and 
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Background/Aims: The BARD score is a model to detect 
advanced liver fibrosis in nonalcoholic fatty liver disease 
(NAFLD) patients. The aims of this study were to identify ad-
ditional factors and then to build an enhanced version of 
the BARD score. Methods: One hundred seven patients with 
biopsy-proven NAFLD were enrolled retrospectively. Logistic 
regressions were performed to identify independent risk fac-
tors for advanced liver fibrosis (stage 3 or 4). An enhanced 
model of the BARD score (BARDI score) was built and evalu-
ated with a receiver operating characteristic (ROC) curve. 
Results: In multivariate analysis, age (odds ratio [OR], 0.89; 
p=0.04), aspartate aminotransferase/alanine aminotrans-
ferase ratio (OR, 1.73; p<0.01), and international normalized 
ratio (INR) (OR, 8.85; p<0.01) were independently significant 
factors. The BARDI score was created by adding the INR to 
the BARD. The area under the ROC curve of the BARDI score 
was significantly larger than that of the BARD score (0.881 vs 
0.808, p<0.01). A BARDI score of 3 or more showed a posi-
tive predictive value (PPV) of 51.0% and a negative predictive 
value (NPV) of 96.0%. Conclusions: The BARDI score had an 
improved PPV over the BARD score and maintained an excel-
lent NPV. Further study is warranted for its external validation 
and comparison with other models. (Gut	Liver	2013;7:323-
328)
Key	Words: Non-alcoholic fatty liver disease; Liver cirrhosis; 
International normalized ratio
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common 
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type of liver disease in the developed countries. About 30% of 
adults have this disease.1 The spectrum of NAFLD is diverse, 
ranging from simple steatosis to nonalcoholic steatohepatitis 
(NASH), which can lead to cirrhosis. The mainstream manage-
ment strategy for NAFLD is regular follow-up with risk factor 
modification and early detection of liver fibrosis.2 Therefore, the 
early detection of liver fibrosis is very important.
The gold standard for detecting liver fibrosis is liver biopsy. 
However this procedure is both risky and expensive, making it 
difficult for patients to undergo repeated procedures.3,4 Further, 
the NAFLD patients stay asymptomatic usually until its final 
stages, making it difficult for the clinician to decide when to 
recommend biopsy, which can result in delayed diagnosis and 
management of liver cirrhosis. Several imaging methods which 
use ultrasound, computed tomography or magnetic resonance 
imaging (MRI) have been introduced to detect liver fibrosis ear-
ly,5-10 but these methods are still expensive and available only 
in limited places.
Several models using demographic and clinical variables 
have been developed that can be used to predict liver fibrosis in 
NAFLD patients. However, some of these were not made specifi-
cally for NAFLD patients,11-13 and some models require a liver 
fibrosis panel which is not broadly used.12,14 The BARD score15 
and the NAFLD fibrosis score16 are the models which were ini-
tially made specifically for NAFLD and do not require a special 
test. The main strength of the BARD score over the NAFLD 
fibrosis score is its simplicity. The components of the BARD 
score: body mass index (BMI), aspartate aminotransferase (AST)/
alanine aminotransferase (ALT) ratio and diabetes, are all widely 
available in clinical practices. The score can be added up simply, 
without the use of a calculator. Considering the high prevalence 
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of NAFLD, it is very important that general physicians have a 
simple method to routinely screen patients for advanced liver 
fibrosis. The limitation of the BARD score is its high false posi-
tivity. If a patient, for example, has diabetes and a BMI of 28 
kg/m2 (BARD score, 2), this patient will be classified as having 
a high risk of advanced liver fibrosis even though the patient 
has an AST/ALT ratio of less than 0.8 and no liver fibrosis. The 
positive predictive value (PPV) of a BARD score of 2 or more 
was 43% for advanced liver fibrosis in its initial development.15 
A prospective study has shown the PPV of a BARD score of 
2 or more to be only 36.1% for advanced liver fibrosis, which 
is lower than PPVs of other clinical models.5 This low PPV of 
BARD score means that a significant number of patients will 
have false positive results and may end up having unnecessary 
imaging tests and risky liver biopsies.
In this study, we evaluated the performance of the BARD 
score in our NAFLD patients and built an enhanced model of 
the BARD score by finding additional variables in NAFLD pa-
tients.
MATERIALS AND METHODS
1. Data sources and elements
All patients with NASH, whose diagnoses were confirmed 
by liver biopsy between 2002 and 2006 at Cabell Huntington 
Hospital/Marshall University Medical Center, were enrolled ret-
rospectively. The diagnostic criteria for NASH were used as de-
scribed in literature previously.17 Any patients who had a history 
of alcohol abuse in their medical records, serologic evidence of 
hepatitis virus infection, or history of other liver disease, such as 
hemochromatosis, alpha-1 antitrypsin deficiency, Wilsons’ dis-
ease, autoimmune hepatitis, primary biliary cirrhosis, or primary 
sclerosing cholangitis, were excluded. Also the patients who 
had an age of less than 18 years old at the time of biopsy were 
excluded.
Demographics (age, sex, weight, and height), comorbidities 
(hypertension, diabetes, and hyperlipidemia), and laboratory 
information (liver profile, lipid profile, serum creatinine, and in-
ternational normalized ratio [INR]) tested within a month before 
the biopsy were obtained from the medical records. Hyperten-
sion, diabetes, and hyperlipidemia patients were defined as those 
who were previously diagnosed with these diseases by physi-
cians, or those who took antihypertensive medications, hypo-
glycemic agents/insulin, or lipid-lowering agents at the time of 
biopsy. The liver profile, lipid profile and serum creatinine level 
were measured using ADVIA® 1650 Chemistry System (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). Protamine was mea-
sured using BCS® System (Siemens Healthcare Diagnostics). The 
INR was calculated from the protamine level by SoftLab® (SCC 
Soft Computer, Clearwater, FL, USA). Pathological reports made 
by two pathologists for clinical purposes were used. The extent 
of fibrosis was staged as follows: stage 0 was defined as no fi-
brosis. Enlarged fibrotic portal tracts were classified as stage 1. 
Periportal or portal-portal septa but intact architecture was clas-
sified as stage 2. Fibrosis with architectural distortion without 
cirrhosis as stage 3, and probable or definite cirrhosis as stage 
4.17 We classified stages 3 and 4 fibrosis as advanced fibrosis 
and stages 0, 1, and 2 as nonadvanced fibrosis. This study was 
approved by Marshall University Institutional Review Board.
2. Statistical method
The chi-square test and Fisher’s exact test were used for the 
categorical variables as appropriate, and a Wilcoxon rank sum 
test was used for the continuous variables to compare between 
advanced and nonadvanced fibrosis groups. A box plot was cre-
ated to show the relationship between variables and the severity 
of fibrosis. The variables which were significantly associated 
with the severity of fibrosis in univariate analyses were selected 
for the multivariate logistic regression. A Wald chi-square test 
was used for the statistical significance testing in the logistic 
regression.
The independent predictors in our multivariate model were 
incorporated into the BARD score model to make an enhanced 
model. A receiver operating characteristics (ROC) curve was 
plotted for both the BARD score model and our enhanced model 
to evaluate their abilities to identify advanced fibrosis in NAFLD 
patients. The area under the ROC curve (AUROC) was calculated 
and a likelihood ratio test was performed to compare the mod-
els. As an independent validation data set was not available, a 
20-fold cross validation was performed as internal validation.18
A p-value of 0.05 was used as the cutoff of statistical sig-
nificance. Statistical analyses were conducted using the SAS 
9.1 statistical software package (SAS Institute, Cary, NC, USA). 
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was used to 
create the box plot and ROC curve.
RESULTS
Of the 135 patients who were identified initially, 28 of pa-
tients were excluded because of our exclusion criteria: 10 al-
coholic hepatitis, nine viral hepatitis, six pediatric patients, two 
hemochromatosis, and one patient with lack of data. Finally, 
107 patients were included in this study. Twenty-two patients 
had stage 0 fibrosis, 20 patients had stage 1, 31 patients had 
stage 2, 18 patients had stage 3, and 16 patients had stage 4 fi-
brosis. As shown in Table 1, the median age was 48.9. Most (79%) 
of the patients had a BMI of more than 28 kg/m2 and there were 
more females than males in both of nonadvanced and advanced 
fibrosis groups. Age, BMI, and sex did not show any significant 
difference between the two groups. Of the laboratory test re-
sults, ALT, AST/ALT ratio, bilirubin, INR, cholesterol, and high 
density lipoprotein levels were significantly different between 
the advanced and nonadvanced liver fibrosis groups.
Of the comorbidities, only hypertension was significantly 
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different between the two fibrosis groups. About 33% of the 
patients had diabetes. The difference in frequencies of diabetes 
and hyperlipidemia between the two fibrosis groups didn’t reach 
a level of statistical significance (Table 1).
Age, BMI, AST/ALT ratio, INR, bilirubin, cholesterol, diabetes, 
and hypertension were included initially in multivariate logistic 
regression. Age, BMI, and diabetes were included because these 
had been the important variables in the previous studies. After 
stepwise selection, age, AST/ALT ratio, and INR were the inde-
pendently significant factors for advanced fibrosis. Bilirubin, 
diabetes, and hypertension were not independently significant, 
even though these variables remained in the final model (Table 
2).
The BARD score was calculated and its ROC curve was cre-
ated using our study sample. An enhanced model of BARD 
score, BARDI score, was generated by adding the INR to the 
components of the BARD score model. To keep the character 
of the BARD score, the same criteria (BMI ≥28 kg/m2 and AST/
ALT ratio ≥0.8) were used in the BARDI score. For the INR, the 
ROC curve was generated and the maximum point of sensitiv-
ity plus specificity was chosen as a cutoff (INR, 1.07). Forced 
entry multivariate logistic regression was performed again us-
ing BMI, AST/ALT ratio, diabetes and INR. The coefficients (β) 
of variables in this multivariate logistic regression were used 
for the BARDI scoring system. AST/ALT ≥0.8 (β=3.21) received 
three credits, diabetes (β=1.22) received one credit, and an INR 
≥1.07 (β=2.01) received two credits. A BMI ≥28 kg/m2 (β=0.12) 
received one credit even with a low β in order to keep the char-
acter of the BARD score in the BARDI score. The ROC curve of 
this BARDI model showed better performance than the BARD 
model (Fig. 1). The AUROC of the BARDI model was signifi-
cantly better than the AUROC of the BARD model (0.881 vs 
Table 1. Demographic and Clinical Characteristics of Patients 
Characteristic Total Nonadvanced (n=73) Advanced (n=34) p-value*
Age, yr 48.9 (40.9–50.0) 48.2 (39.7–54.5)
n=73
50.5 (42.3–58.2)
n=34
0.14
BMI, kg/m2 35.9 (29.6–44.7) 35.08 (28.82–43.82)
n=63
40.97 (31.35–52.78)
n=31
0.08
Male sex 41 (38.3) 27 (37)
n=73
14 (41)
n=34
0.68
AST, U/L 55.0 (36.0–81.0) 55.0 (39.0–81.0)
n=65
54.5 (30.0–80.0)
n=34
0.48
ALT, U/L 63.0 (29.0–105.0) 75.0 (42.0–122.0)
n=65
33.5 (26.0–69.0)
n=34
<0.01
AST/ALT ratio 0.90 (0.68–1.31) 0.74 (0.62–1.08)
n=65
1.25 (0.99–1.56)
n=34
<0.01
Bilirubin, mg/dL 0.50 (0.40–0.80) 0.40 (0.30–0.60)
n=64
0.60 (0.40–1.00)
n=34
0.01
INR 1.02 (0.95–1.14) 0.97 (0.94–1.05)
n=64
1.14 (1.05–1.46)
n=31
<0.01
Creatinine, mg/dL 1.00 (0.90–1.10) 1.00 (0.90–1.10)
n=62
1.00 (0.90–1.10)
n=33
0.44
Total cholesterol, mg/dL 183.5 (162.0–219.0) 202.0 (168.0–222.0)
n=35
172.0 (151.0–199.0)
n=21
0.05
LDL, mg/dL 106 (85.5–133.0) 116.0 (87.0–145.0)
n=35
101.0 (82.0–117.0)
n=21
0.10
HDL, mg/dL 42.5 (35.0–50.5) 47.0 (35.0–57.0)
n=35
38.0 (35.0–43.0)
n=21
0.03
Triglyceride, mg/dL 157.0 (115.0–255.0) 159.0 (128.5–278.5)
n=36
140.0 (98.0–207.0)
n=21
0.15
Diabetes 34 (32.7) 21 (29.2) 13 (40.6) 0.25
Hypertension 51 (49.0) 30 (41.7) 21 (65.6) 0.02
Hyperlipidemia 30 (28.9) 17 (23.6) 13 (41.6) 0.08
Data are presented as medians (interquartile ranges) or number (%).
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; LDL, low density 
lipoprotein; HDL, high density lipoprotein.
*Comparison between nonadvanced vs advanced disease. Chi-square tests for sex, diabetes, hypertension, and hyperlipidemia. Wilcoxon Rank-
Sum tests for other variables.
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0.808, p<0.01). Comparing a BARD score of 2 or more with a 
BARDI score of 2 or more, the PPV was 45.8% for the BARD 
and 45.0% for the BARDI, which were not much different in 
our subjects. The negative predictive values (NPV) were 100% 
in both the BARD and BARDI scores. When comparing a BARDI 
score of 3 or more with a BARD of score 2 or more, the BARDI 
score showed higher specificity (49.0% vs 34.7%) without losing 
much sensitivity (96.3% vs 100%). The PPV for a BARDI score 
of 3 or more was 51.0%, while the PPV for a BARD score of 2 
or more was 45.8%. The NPV for a BARDI score of 3 or more 
was 96.0% and NPV for a BARD score of 2 or more was 100% 
(Table 3). Twenty fold cross validation of the BARDI model 
showed 80.39% accuracy with a standard error of 0.75%. We 
tried to incorporate age, bilirubin, and hypertension respectively 
into the BARDI model. However, these variables did not increase 
the AUROC significantly and were not included in the final 
model (data not shown).
DISCUSSION
We developed an enhanced model (BARDI score), by adding 
the INR, which was known to have correlation with liver fibro-
sis.13,16 As shown in Table 3, the BARDI score kept the simplicity 
and strength of the BARD score. All patients with a BARD score 
of 2 or more should have a BARDI score of 2 or more. A BARDI 
score of 2 or more performed similarly to a BARD score of 2 or 
more. When a BARDI score of 3 or more was compared with a 
BARD score of 2 or more, the BARDI score showed an improved 
PPV and kept an excellent NPV for detecting advanced liver 
fibrosis.
Using 2 or more of the BARD score is just the same as having 
one of either two risk factors (obesity and diabetes) or an AST/
ALT ratio ≥0.8 as criteria for advanced fibrosis. If the patient has 
two risk factors with an AST/ALT ratio less than 0.8, the patient 
will be classified as high risk for advanced fibrosis. Usually, 
Table 3. Comparison between BARD and BARDI Scores Using Our 
Study Sample
Sensitivity Specificity PPV NPV
BARD
≥0 1.000 0.000 0.355 1.000
≥1 1.000 0.082 0.375 1.000
≥2 1.000 0.347 0.458 1.000
≥3 0.852 0.673 0.590 0.892
≥4 0.333 0.918 0.692 0.714
BARDI
≥0 1.000 0.000 0.355 1.000
≥1 1.000 0.082 0.375 1.000
≥2 1.000 0.327 0.450 1.000
≥3 0.963 0.490 0.510 0.960
≥4 0.926 0.612 0.568 0.938
≥5 0.852 0.796 0.697 0.907
≥6 0.704 0.878 0.760 0.843
≥7 0.259 0.980 0.875 0.706
BARD area under receiver operating characteristic curve 0.808. BAR-
DI area under receiver operating characteristic curve 0.881. BARDI 
score is the sum of the points below. 
If body mass index ≥28 kg/m2, then 1 point. If aspartate aminotrans-
ferase/alanine aminotransferase ratio ≥0.8, then 3 points. If diabetes 
present, then 1 point. If international normalized ratio ≥1.07, then 2 
points.
PPV, positive predictive value; NPV, negative predictive value. 
Fig. 1. Receiver operating characteristic (ROC) curve of BARD and 
BARDI score for advanced liver fibrosis. Area under ROC curve for 
BARDI model, 0.881 (95% confidence interval [CI], 0.804 to 0.958). 
Area under ROC curve for BARD model, 0.808 (95% CI, 0.712 to 0.904). 
Seventy-six patients were used for this ROC curve after the exclusion 
of patients with missing values.
*Likelihood ratio test.
Table 2. Multivariate Logistic Regression Analysis for the Prediction 
of Advanced Liver Fibrosis
Multivariate
OR (95% CI) p-value*
Age 0.89 (0.79–1.00) 0.04
AST/ALT ratio 1.73 (1.17–2.56)† <0.01
Bilirubin 0.09 (0.01–1.04) 0.05
INR 8.85 (1.77–44.11)‡ <0.01
Diabetes 9.08 (0.62–131.93) 0.11
Hypertension 13.80 (0.82–233.29) 0.07
Stepwise selection after including age, body mass index, AST/ALT 
ratio, INR, bilirubin, cholesterol, diabetes, and hypertension. The AST/
ALT ratio and INR were multiplied by 10 to match the interval scale 
with other variables.
OR, odds ratio; CI, confidence interval; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; INR, international normalized 
ratio.
*Wald chi-square test; †OR for the 0.1 change of AST/ALT ratio; ‡OR 
for the 0.1 change of INR.
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diabetic patients have a high prevalence of obesity.19 All these 
obese diabetic patients will be classified into the high risk group 
for advanced fibrosis, which will result in a lot of false positiv-
ity. In our study, we had a skewed population in terms of BMI 
and most patients received a credit due to obesity (BMI ≥28). 
Among the patients with both diabetes and obesity in our study 
(n=27), many patients (n=11, 40.7%) would have a BARD score 
of 2, even though they did not have advanced liver fibrosis. 
In contrast, a BARDI score of 3 or more cannot be made from 
the risk factors alone. Risk factors need to be combined with 
an INR ≥1.07 to reach a score of 3 or more. This combination 
is the main reason why the BARDI score can decrease the false 
positivity (increase PPV) of the BARD score. The role of AST/
ALT ratio was kept the same in the BARDI score as in the BARD 
score. Any patient with an AST/ALT ratio of 0.8 or more should 
be classified into the possible advanced liver fibrosis group in 
either scoring system.
Age,11-13,16 platelet count,13 albumin,16 bilirubin,13,16 triglycer-
ide,11 impaired fasting glucose level,16 and hypertension15,16 are 
known to be associated with advanced liver fibrosis and some 
of them have been used in other models, as shown in Table 4. 
In our study, we didn’t have enough data for platelet, albumin 
and were not able to compare BARDI score directly with other 
models including NAFLD fibrosis score16 or FIB-4 score.13 As our 
patients did not have liver fibrosis panel, it was also not possible 
to compare the BARDI score with any models (OELF,12,14 ELF14 
models) that used the liver fibrosis panel. Indirect comparison of 
PPV and NPV was also not possible because the PPV and NPV 
would be affected by the prevalence of advanced liver fibrosis 
in each study. However, the indirect comparison of sensitiv-
ity and specificity between models showed promising results. 
For example, an NAFLD fibrosis score showed 82% sensitivity 
and 77% specificity. A BARDI score of 3 or more showed 96% 
sensitivity and 49% specificity. When it comes with the BARDI 
score of 5 or more, the BARDI showed 85% sensitivity and 
79.6% specificity. When the AUROC was compared using the 
previously reported AUROCs of other models, the AUROC 0.881 
of the BARDI score was at least comparable with other models 
(Table 4).
Other imaging studies including ultrasound based transient 
elastography (FibroScan), MR spectroscopy, diffusion weighted 
MRI, and MR elastography have been developed.9 It has been 
shown that these imaging methods have slightly better or 
comparable results to clinical models. In the case of transient 
elastography, the AUROC was reported to be 0.9047 and 0.94.5 
In particular, Wong et al.5 showed the superiority of transient 
elastography to other previous clinical models for the diagnosis 
of advanced liver fibrosis. However, these imaging techniques 
cost more expenses and limited to only a small number of cen-
ters. Considering that NAFLD is a very common disease with 
a prevalence of about 30%,1 there should be a way that clini-
cians can evaluate a patient’s risk of liver fibrosis in their offices 
before they refer them to specialized centers. If the assessment 
can be done using simple usual lab tests, many at risk patients 
can be detected or excluded before they go for an imaging test. 
After first screening with a clinical model, a physician still can 
perform imaging tests, which can give some information before 
the liver biopsy. An imaging test can differentiate a diffuse le-
sion from a local lesion and can also provide information about 
the character of a localized lesion, including possible mass like 
lesion, infection and so on. Then patient can opt for biopsy if it 
is indicated through the clinical model and imaging test.
Our study had several limitations. We had only 107 patients 
to analyze, which made it hard to split our subjects for exter-
nal validation. Instead, we performed 20-fold cross validation, 
which showed a good performance of the BARDI score. Another 
limitation was derived from the restrictions of retrospective 
study. All information was gathered using the medical records 
which had been produced for clinical purposes only. The infor-
mation was not complete enough to compare several previous 
models using our study subjects. We were able to calculate only 
the BARD score for our subjects. Also some medical records 
Table	4. Previously Reported Models for Advanced Liver Fibrosis in NAFLD
Model Variable Cut-off AUROC Sensitivity, % Specificity, % PPV, % NPV, %
BAAT11,* BMI, age, ALT, triglycerides 1 0.84 100 47 45 100
FIB-45,† Age, AST, ALT, platelet 1.30 0.80 65.1 80.2 50.6 88.0
OELF14 Age, P3NP, TIMP-1, HA 0.375 0.87 89 96 80 98
ELF14 P3NP, TIMP-1, HA 0.3576 0.90 80 90 71 94
NAFLD fibrosis score16 Age, BMI, IFG or DM, AST/ALT, platelet, albumin -1.455 0.88 82 77 56 93
ELF+NAFLD fibrosis 
score14
P3NP, TIMP-1, HA, BMI, IFG or DM, AST/ALT, 
platelet, albumin
-0.2826 0.98 91 96 77 99
BARD score15 BMI, AST/ALT, DM ≥2 0.81 NA NA 43 96
NAFLD, nonalcoholic fatty liver disease; AUROC, area under receiver operating characteristic curve; PPV, positive predictive value; NPV, negative 
predictive value; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; P3NP, amino-terminal propeptide of 
type III collagen; TIMP-1, tissue inhibitor of matrix metalloproteinase 1; HA, hyaluronic acid; IFG, impaired fasting glucose; DM, diabetes mel-
litus; NA, not available.
*AUROC, PPV, NPV were calculated to detect stage 2 or higher; †AUROC, PPV, NPV data were from the study.
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were not detailed regarding alcohol consumption. We had to 
exclude any patients who drank unspecified amounts of alcohol 
from our study. Also, our study was based on patients who had 
already had liver biopsies, indicating that the studies subjects 
may be sicker than the general population. Actually, all previ-
ous clinical models were made using the patient population who 
had received or had decided to have liver biopsy as well. The 
performance of these models should be evaluated prospectively 
in general population.
In conclusion, the INR was an independently significant fac-
tor for advanced liver fibrosis. We developed the BARDI score 
by adding the INR to the BARD score, resulting in an enhanced 
model that was still easy to calculate and had better perfor-
mance than the BARD in predicting advanced liver fibrosis. 
Using the BARDI score would decrease false positivity with an 
excellent NPV, and eventually prevent unnecessary imaging 
tests or risky liver biopsies. Further external validation study 
and prospective study are needed to confirm this finding.
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